التفاصيل البيبلوغرافية
| العنوان: |
A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma. |
| المؤلفون: |
Gordon, Max J., Dubois, Sigrid, Bryant, Bonita, Ng, Samuel, Conlon, Kevin, Miljkovic, Milos D., Waldmann, Thomas, Roschewski, Mark |
| المصدر: |
Leukemia & Lymphoma; Jul2024, Vol. 65 Issue 7, p1008-1011, 4p |
| مصطلحات موضوعية: |
ALEMTUZUMAB, T-cell lymphoma, INTERLEUKIN-15, SEZARY syndrome, REGULATORY T cells, ANTIBODY-dependent cell cytotoxicity, KILLER cells, CUTANEOUS T-cell lymphoma |
| مستخلص: |
A phase 1 study was conducted to investigate the combination of interleukin-15 (IL-15) and avelumab in patients with relapsed or refractory T-cell lymphoma. IL-15 is known to stimulate NK and T-cell functions, and previous studies have shown that it can enhance the activity of anti-tumor monoclonal antibodies. Avelumab is an anti-PDL1 antibody that functions as an immune checkpoint inhibitor. The study enrolled eight patients, and although the maximum tolerated dose was not established due to early closure, two patients with PTCL-NOS had a partial response and two had stable disease. The results of this study can inform ongoing efforts to improve immunotherapy for T-cell lymphomas. [Extracted from the article] |
|
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
PDF full text from Publisher